United Imaging, a medical imaging and radiotherapy equipment maker, has secured the US Food and Drug Administration (FDA) clearance for its uMR Jupiter 5 tesla (5T) MRI system.
It is claimed to be the first ultra-high field system approved for whole-body applications. The system is also the first of any field strength to be equipped with an eight-channel whole-body multi-transmit system.
Go deeper with GlobalData
United Imaging chairman and co-CEO Dr Al Zhang said: “For decades, whole body applications above 3T have been elusive, and this system was targeted to open those doors. uMR Jupiter breaks new ground and defines a new technical category of systems.”
The uMR Jupiter 5T MRI system is said to transcend the traditional limitations of ultra-high-field imaging.
United Imaging asserts that this system provides clinicians with the ability to observe anatomical structures with clarity and in detail.
The system’s ultra-high-field magnet strength enhances resolution and signal-to-noise ratio, which could significantly improve diagnostic accuracy, claimed the company.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIt has been specifically designed to improve imaging of traditionally difficult areas such as the heart, abdomen and pelvis.
The technology aims to enable radiologists to detect and diagnose medical conditions with greater precision across a broader range of examinations.
United Imaging North America president and chief commercial officer Jeffrey M Bundy said: “Our investments in R&D and a highly efficient vertical integration strategy for our manufacturing have repeatedly led to breakthroughs – especially ones that help us achieve our mission of Equal Healthcare for All.
“We have always prioritised innovation that can make a broad clinical impact. Because it is aimed first and foremost at bringing ultra-high-field into greater clinical use, we believe it will have an exciting impact across our industry, and for clinical patients across the globe who have never had access to ultra-high-field in the past.”
